Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia - a Double Blind, Placebo Controlled Trial

NCT00727103 Phase 4 COMPLETED

The aim of the proposed pilot study is to find out whether varenicline (ChantixTM) treatment decreases alcohol use and smoking in patients with schizophrenia or schizoaffective disorder. Varenicline may also improve cognition (memory and concentration) and negative symptoms (e.g. poor attention, poverty of speech, apathy, affective flattening, anhedonia) in patients with schizophrenia and comorbid nicotine and alcohol dependence.

Details

Lead sponsor	State University of New York - Upstate Medical University
Phase	Phase 4
Status	COMPLETED
Enrolment	10
Start date	2008-07
Completion	2011-05

Conditions

• Schizophrenia
• Schizoaffective Disorder
• Alcohol Dependence
• Nicotine Dependence

Interventions

• Varenicline
• Placebo

Primary outcomes

• The primary outcome measure for alcohol use will be the number of drinks/week at the end of the treatment phase, relative to baseline and during-treatment data. — 8 weeks

Countries

United States